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GWAS of thyroid stimulating hormone highlights
pleiotropic effects and inverse association with
thyroid cancer
Wei Zhou et al.#
Thyroid stimulating hormone (TSH) is critical for normal development and metabolism. To
better understand the genetic contribution to TSH levels, we conduct a GWAS meta-analysis
at 22.4 million genetic markers in up to 119,715 individuals and identify 74 genome-wide
significant loci for TSH, of which 28 are previously unreported. Functional experiments show
that the thyroglobulin protein-altering variants P118L and G67S impact thyroglobulin secre-
tion. Phenome-wide association analysis in the UK Biobank demonstrates the pleiotropic
effects of TSH-associated variants and a polygenic score for higher TSH levels is associated
with a reduced risk of thyroid cancer in the UK Biobank and three other independent studies.
Two-sample Mendelian randomization using TSH index variants as instrumental variables
suggests a protective effect of higher TSH levels (indicating lower thyroid function) on risk of
thyroid cancer and goiter. Our findings highlight the pleiotropic effects of TSH-associated
variants on thyroid function and growth of malignant and benign thyroid tumors.
https://doi.org/10.1038/s41467-020-17718-z OPEN
#A list of authors and their affiliations appears at the end of the paper.
NATURE COMMUNICATIONS |         (2020) 11:3981 | https://doi.org/10.1038/s41467-020-17718-z | www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
Normal thyroid function is essential for proper growth anddevelopment, and for metabolic functions. Approximately20 million people in the United States are affected by
thyroid disorders and 12% of the population is expected to
develop thyroid conditions over their life span1. Thyroid-
stimulating hormone (TSH) is secreted by the pituitary gland
and stimulates the growth of the thyroid gland, and its synthesis
and secretion of thyroid hormones. These include thyroxine (T4),
most of which is converted to its more bioactive form, 3,3′,5-
triiodothyronine (T3). TSH levels are negatively regulated by T3
and T4, and lower or higher levels than the reference range,
respectively, usually suggest that the thyroid gland is overactive as
in primary hyperthyroidism or underactive as in primary hypo-
thyroidism. The complex inverse relationship between TSH and
thyroid hormones means TSH is a more sensitive marker of
thyroid status, a feature that has been used to identify individuals
with thyroid dysfunction2.
Thyroid disorders affect multiple organs and are associated
with a range of clinical consequences, including an increased risk
of metabolic disorders and cardiovascular mortality3–6. Over the
past few decades, a steady increase of the incidence rates of non-
medullary thyroid cancer (henceforth referred as thyroid cancer)
has been observed in most areas of the world, including in Eur-
ope7. Previous studies have led to inconsistent conclusions on the
relationship between TSH levels and thyroid cancer risk8. Several
studies have observed an association between low TSH levels,
which can occasionally occur as a consequence of autonomous
thyroid nodules and an increased risk of thyroid cancer8–13. In
contrast, several studies have indicated that TSH promotes the
growth of thyroid cancers8,14–16, which has led to the recom-
mendation to lower TSH levels among people with thyroid cancer
to reduce the risk of cancer recurrence. Two initial genome-wide
association studies (GWAS) identified five significant loci for
thyroid cancer in Europeans and the risk alleles of all five loci
have been associated with decreased TSH levels17,18. In contrast, a
more recent GWAS identified five additional loci associated with
thyroid cancer, none of which were even nominally associated
with TSH19. A recent two-sample Mendelian randomization
study suggested a causal inverse association between TSH levels
and overall cancer risk, including thyroid cancer20. Additional
studies are needed to clarify the role of TSH and TSH-associated
variants in thyroid cancer.
Twin studies have shown TSH levels are moderately heritable,
with estimates up to 65%21. Previous TSH GWAS studies have
identified 46 independent TSH-associated loci17,22,23, accounting
for 9.4% of TSH variance, thus leaving a large proportion of the
TSH heritability unexplained23,24. With the goal of identifying the
missing genetic components for TSH to further understand its
underlying genetic architecture and impact on thyroid cancer, we
perform a GWAS meta-analysis for TSH levels on the
population-based Nord-Trøndelag Health Study (HUNT study)
(N= 55,342)25, Michigan Genomics Initiative26 (MGI, N=
10,085), and the ThyroidOmics consortium (up to N=
54,288 samples)23.
To investigate the genetic relationship between TSH and
thyroid cancer, and other human diseases, we examine phenome-
wide associations in the UK Biobank (UKBB)27 for TSH-
associated index variants. We also conduct phenome-wide asso-
ciation tests for the polygenic scores (PGS) of TSH in the UKBB
and the FinnGen study. We observe an association between high
TSH PGS and low thyroid cancer risk, and replicate that obser-
vation in two other study populations from Columbus, USA and
Iceland19. To evaluate the potential causality of TSH on thyroid
cancer, we perform a two-sample Mendelian Randomization
analysis using the TSH-associated top association signals as
instrumental variables and the thyroid cancer GWAS results on
736,049 individuals (4146 cases and 731,903 controls) from a
meta-analysis of UKBB27,28, MGI26, and results from a previous
meta-analysis for thyroid cancer based on a Icelandic data set
from deCODE (referred to as deCODE in this manuscript), as
well as four other case–control data sets with European ancestry
as reported in Gudmundsson et al.19.
Results
Discovery of genetic loci for TSH. We identified 74 loci asso-
ciated with TSH (Table 1, Supplementary Data 1 and 2, and
Supplementary Fig. 1) in our meta-analysis of the HUNT study
(N= 55,342), the MGI biobank (N= 10,085), and the Thyr-
oidOmics consortium23 (up to N= 54,288). Twenty-eight of the
74 loci have not been previously reported for TSH17,22,23
(Table 1). To identify secondary independent association signals,
we performed stepwise conditional analysis within each locus
using GCTA-COJO29 based on GWAS summary statistics from
the meta-analysis of HUNT, MGI, and ThyroidOmics, and the
linkage disequilibrium (LD) correlation between variants esti-
mated in HUNT. We observed additional associations in 1 novel
TSH locus (B4GALNT3) and 11 previously known TSH loci
(Table 1 and Supplementary Data 2). In total, 99 independent top
variants have been identified at the 74 loci, explaining 13.3% of
the variance of TSH levels.
Despite having only moderate effect sizes, top variants in
several novel TSH loci point to nearby genes with a known or
suspected link to thyroid function (Table 1 and Supplementary
Fig. 2). An intronic variant (rs10186921) in the thyroid adenoma-
associated gene THADA was identified to be associated with TSH.
THADA has been identified as a somatic mutated/rearranged
gene in papillary thyroid cancer30 and observed to be truncated in
thyroid adenoma31. Although THADA is known to play a role in
cold adaptation, obesity, and type 2 diabetes, its role in thyroid
function remains elusive32,33. A rare missense variant
rs145153320 in gene B4GALNT3 is associated with TSH
(minor allele frequency in HUNT (MAFHUNT)= 0.25%, effect
sizeHUNT= 0.49 standard deviation (SD), 95% confidence interval
(CI)= 0.35–0.63 SD, P-valueHUNT= 1.00 × 10−11) and is 11
times more frequent in the Norwegian HUNT samples than in
other non-Finnish Europeans34. The WNK1-B4GALNT3 gene
fusion has been identified in papillary thyroid carcinoma35.
Two novel independent rare coding variants with effect sizes
larger than one SD were identified in the known TSH locus TSHR,
which encodes the TSH receptor. Both variants were only observed
in HUNT. The rare missense variant TSHR p.R609Q (rs139352934,
MAFHUNT= 0.20%, effect sizeHUNT= 1.1 SD, 95% CI= 0.94–1.26
SD) is the most significant variant in the locus (P-valueHUNT=
2.66 × 10−41) followed by p.A553T (rs121908872, MAFHUNT=
0.07%, effect sizeHUNT= 1.63 SD, 95% CI= 1.36–1.90 SD,
P-valueHUNT= 2.79 × 10−32). TSHR p.R609Q (rs139352934) is
22 times more frequent in HUNT than in other non-Finnish
Europeans34. TSHR p.R609Q has been reported to aggregate in a
family with non-autoimmune isolated hyperthyrotropinemia36 and
TSHR p.A553T has been previously detected in a family with
congenital hypothyroidism37.
As single-variant association tests may lack power for rare
variants (MAF ≤ 0.5%) and to search for genes with multiple rare
protein-altering variants, we performed exome-wide gene-based
SKAT-O38 tests as implemented in SAIGE-GENE39 to identify
rare coding variants associated with TSH. We grouped missense
and stop-gain variants with MAF ≤ 0.5% and imputation quality
score ≥ 0.8 within each gene and tested 10,071 genes with at least
two variants. This analysis identified two genes, TSHR and
B4GALNT3, as significantly associated with TSH (P-value < 2.5 ×
10−6; Supplementary Table 1 and Supplementary Fig. 3). Rare
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variants in both genes associated with TSH were also identified
from single-variant analysis. After conditioning on the two rare
variants in TSHR that were genome-wide significant in the single-
variant analysis (P-value < 5 × 10−8), rs121908872 and
rs139352934, the gene TSHR was still exome-wide significant
with P-value 2.87 × 10−8, while B4GALNT3 was no longer
significantly associated with TSH with P-value 0.3 after
conditioning on the top variant rs145153320.
Fine-mapping for potentially causal variants among TSH loci.
To identify potentially causal variants at TSH loci, we conducted
fine-mapping using SuSiE40, which estimates the number of
causal variants and obtains credible sets of variants with 95%
cumulative posterior probability through Iterative Bayesian
Stepwise Selection41 (Supplementary Data 3). The LD matrix
used in SuSiE was calculated based on HUNT. We identified eight
independent causal variants at the TSHR locus by fine-mapping
using SuSiE40 and seven independent association signals by the
stepwise conditional analysis (Supplementary Data 2), suggesting
allelic heterogeneity at the TSHR locus.
In addition, fine-mapping by SuSiE40 and stepwise conditional
analysis identified two association signals in the locus of the
thyroglobulin gene (TG). TG encodes a highly specialized
homodimeric multidomain glycoprotein for thyroid hormone
biosynthesis27, it is the most highly expressed gene in the thyroid
gland and its protein product represents roughly half the protein
of the entire thyroid gland42,43. The TG locus has been reported
in a recent TSH GWAS23. The 95% credible set for each causal
association contains one missense variant that is in strong LD
with the most strongly associated intronic variant (Supplemen-
tary Table 2 and Supplementary Fig. 4). In the HUNT study, the
missense variant TG p.G67S (rs116340633, MAF= 1.8%, effect
size= 0.77 SD, 95% CI= 0.73–0.82 SD, P-value= 1.07 × 10−21)
is in strong LD (r2= 0.99) with the most strongly associated
variant rs117074997 (intronic). At the other association signal,
missense variant TG p.P118L (rs114322847, MAF= 2.4%, effect
size= 0.84 SD, 95% CI= 0.82–0.87 SD, P-value= 1.87 × 10−26)
is in strong LD (r2= 0.92) with the most strongly associated
variant rs118039499 (intronic) (Supplementary Table 2 and
Supplementary Fig. 4). TG p.P118L has been previously detected
among familial cases with congenital hypothyroidism44. TG p.
P118L (rs114233847) is significantly associated with nontoxic
nodular goiter (odds ratio (OR)= 2.69, 95% CI= 2.05–3.54,
P-value= 5.8 × 10−12) in the UKBB27,28, while the association of
TG p.G67S (rs116340633) with nontoxic nodular goiter is
less significant (OR= 1.63, 95% CI= 1.08-2.49, P-value= 2.1 ×
10−2). TG p.P118L has been previously detected in patients with
sporadic congenital hypothyroidism in a Finnish cohort44.
Functional follow-up of missense variants in the gene TG. We
performed site-directed mutagenesis studies to investigate the
impact on the protein expression of TG of the two independent
missense variants, both located in the highly conserved Tg1
domain of unclear function. The protein encoded by the human
TG is conserved in mice, with nearly perfect conservation of all
critical amino acid residues, including those that maintain the
protein structure and hormone synthesis45. A cDNA encoding
wild-type mouse Tg (mTg-WT) expressed in 293T cells has
normal synthesis and secretion of thyroid hormones46. We then
introduced the observed human TG variants (rs116340633 and
rs114322847) into the mTg cDNA. 293T cells were either
untransfected or transfected with pcDNA3.1 in which a cyto-
megalovirus promoter drives expression of mTg-WT or the p.
P118L or p.G67S Tg variants (mature Tg numbering). Then, we
examined the intracellular vs. secreted levels of the mTg-WT and
these two human Tg variants (Tg-p.P118L and Tg-p.G67S).
Transfected cells were incubated overnight and the culture
medium and cell lysates were analyzed by SDS-polyacrylamide gel
electrophoresis (PAGE) and immunoblotting with anti-Tg anti-
body. The experiment was independently repeated three times
and the results analyzed in a manner that is independent of
transfection efficiency. On average, 74.6% of the total expressed
WT form of mTg was recovered in the media and extracellular :
intracellular (M/C) ratio of mTg was 2.94:1, as expected (between
3:1 and 4:1) (Fig. 1). Compared with the WT, the Tg-
P118L variant showed a significant reduction in the M/C ratio
0.6:1 (P-value= 0.0051) and the Tg-G67S variant also showed a
significant reduction in the M/C ratio 1.96:1 (P-value= 0.0095).
Prioritization of TSH genes, pathways, and tissues. To further
understand the biology underlying TSH associations, we prior-
itized associated genes, tissues, and cell types in which TSH genes
are likely to be highly expressed using Data-driven Expression-
Prioritized Integration for Complex Traits (DEPICT)47 based on
161 loci with TSH association P-value cutoff 1 × 10−5 and
clumped based on LD in HUNT. As expected, the membranes
and thyroid gland are the most strongly associated tissues fol-
lowed by tissues from the digestive system (ileum, gastrointestinal
tract, pancreas, and colon), respiratory system (lung) and acces-
sory organs for eyes (conjunctiva, eyelids, and anterior eye),
although none of the tissues reached the Bonferroni significant
threshold (P-value < 0.05/209) or have false discovery rate (FDR)
< 0.05 (Supplementary Data 4). Based on functional similarity to
other genes among TSH loci, 70 genes at the TSH-associated loci
were prioritized by DEPICT with FDR ≤ 0.01 (Supplementary
Data 5), among which the prioritized genes ZFP36L2,
B4GALNT3, PPP1R3B, FAM109A, GNG12, GADD45A, BMP2,
VEGFC, LPP, and MAL2 were at the novel TSH loci identified in
our meta-analysis (Table 1). In addition, among 14,461 recon-
stituted gene sets, 56 gene sets were enriched among TSH loci
with FDR < 0.01. The most significantly enriched one is the CTSD
PPI subnetwork, followed by gene sets for regulation of phos-
phorylation (Supplementary Data 6).
Pleiotropic effects of TSH loci. To explore the pleiotropic effects
of the TSH loci, we examined associations of the 95 non-human
leukocyte antigen (HLA) independent TSH top variants with
1283 human diseases (PheCodes)27,28,48 and 274 continuous
traits (http://www.nealelab.is/uk-biobank) in the UKBB (variants
23:3612081 and rs121908872 are not available in the UKBB). Due
to the strong associations between HLA variants and auto-
immune diseases49, we excluded two HLA variants associated
with TSH (rs1265091 and rs3104389) in the analysis for pleio-
tropic effects. We identified significant (P-value < 5 × 10−8)
pleiotropic association for 18 out of 95 non-HLA variants across
31 disease phenotypes (Supplementary Fig. 5a and Supplemen-
tary Data 7), including thyroid disorders, diabetes, cardiovascular
disease, digestive system disorders, asthma, and cataracts.
In addition, 34 non-HLA variants were significantly associated
(P-value < 5 × 10−8) with one or more quantitative traits,
including body mass index, lung function measurements, metrics
of bone density, spherical power/meridian measurements, and
blood cell counts (Supplementary Fig. 5b and Supplementary
Data 8). TSH-increasing alleles at one or more loci were asso-
ciated with an increased risk of cardiovascular disease, smaller
body size, reduced bone mineral density, decreased lung function,
and an increased risk of hypothyroidism and a decreased risk of
goiter. These results are generally consistent with previous stu-
dies23. We also examined the associations between the TSH index
variants and free thyroxine levels in the ThyroidOmics
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consortium23. Out of 91 TSH-associated variants, for which
association results with free thyroxine were available, 70 (77%)
have TSH-lowering alleles associated with higher free thyroxine
levels (Supplementary Data 9) (P-valuebinomial= 2.51 × 10−7).
We further examined the association with thyroid cancer for
TSH index variants. We meta-analyzed UKBB27,28 and a previous
meta-analysis of deCODE and four other case–control data sets19
for thyroid cancer in 3359 thyroid cancer cases and 694,949
controls and examined 94 out of 99 TSH non-HLA index variants
that are available in the meta-analysis for thyroid cancer
(Supplementary Data 9). The TSH-increasing alleles of 63 out
of 94 TSH-associated variants (67%) were associated with
reduced thyroid cancer risk (Supplementary Data 9 and
Supplementary Fig. 6a and 6b) (P-valuebinomial= 1.26 × 10−3).
Eighteen out of the 94 TSH-associated variants tested (19%) were
at least nominally associated with thyroid cancer (P < 0.05) (P-
valuebinomial= 1.18 × 10−9). For 16 out of the 18 TSH-associated
variants, the TSH-increasing alleles were associated with reduced
thyroid cancer risk (P-valuebinomial= 1.31 × 10−3, Supplementary
Data 9 and Supplementary Fig. 6c, d). Moreover, when we
examined alleles that predisposed to thyroid cancer17–19, 9 out of
11 had a consistent direction of effect towards lower TSH (P-
valuebinomial= 0.065). Of the six thyroid cancer risk
alleles that were at least nominally associated with TSH level
(P < 0.05), all six variants were associated with lower TSH
(P-valuebinomial= 0.03) (Supplementary Data 10 and Supplemen-
tary Fig. 7).
Associations of polygenic scores of TSH with other phenotypes.
Although individual TSH variants may exhibit pleiotropic effects,
it is also possible that the cumulative effects of TSH-modifying
genetic variants may lead to disease. Therefore, we constructed
PGS from the 95 independent non-HLA TSH top variants
(rs1265091 and rs3104389 are HLA variants and rs121908872
and 23:3612081 were not in UKBB) and examined their asso-
ciation with the 1283 human diseases constructed from Inter-
national Classification of Diseases (ICD) codes in the
UKBB27,28,48. As in the pleiotropy analysis, we excluded the two
HLA variants in the PGS calculation to study the cumulative
genetic effects of TSH-associated variants in non-HLA regions
with human diseases. The TSH PGS was significantly associated
with 10 phenotypes (P-value < 3.9 × 10−5, Bonferroni correction
for 1283 phenotypes), including an increased hypothyroidism risk
and decreased risk of goiter, thyrotoxicosis and hyperhidrosis
(Supplementary Data 11 and Supplementary Fig. 8). We also
evaluated the phenotypic variance (Nagelkerke’s r2)50 explained
by TSH PGS for 596 phenotypes in the UKBB that have at least
500 cases in 280,943 unrelated white British samples (Supple-
mentary Data 12). The phenotypes with highest r2 were nontoxic
nodular goiter (r2= 0.96%), secondary hypothyroidism (r2=
0.46%), and thyrotoxicosis with or without goiter (r2= 0.16%). In
FinnGen, we also observed that high TSH PGS was associated
with high risk of hypothyroidism and low risk of goiter. High
TSH PGS in FinnGen was marginally associated with an increase
in risk of depression (OR= 1.03 (per SD of TSH PGS), 95% CI=
1.01–1.05, P-value= 1.7 × 10−3) and a reduced risk of pregnancy
hypertension (OR= 0.95 (per SD of TSH PGS), 95% CI=
0.92–0.98, P-value= 9 × 10−4). The phenome-wide association
results for the TSH PGS in FinnGen are shown in Supplementary
Data 13 and Supplementary Fig. 9. Depressive symptoms
and hypertension during pregnancy have been observed to be
clinically associated with hypothyroidism and thyroid dysfunc-
tion51–53, respectively. However, their genetic associations have
not been extensively studied.
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In the UKBB, TSH PGS was significantly associated with a
decreased risk of thyroid cancer (OR= 0.86 (per SD of
TSH PGS), 95% CI= 0.78–0.96, P-value= 5.8 × 10−3,
Supplementary Data 11 and Fig. 2). Compared with the rest of
the samples, the OR (95% CI) for thyroid cancer of
individuals with TSH PGS in the lowest quintile was 1.29
(1.01–1.64) and the OR for thyroid cancer of individuals with
TSH PGS in the highest quintile was 0.66 (0.49–0.89), suggesting
the protective effects of TSH-increasing genetic variants on
thyroid cancer risk.
We successfully replicated the association between high TSH
PGS and low thyroid cancer risk in study populations from
Columbus, USA19 (OR= 0.19, 95% CI= 0.10–0.37, P-value=
2.1 × 10−7) and deCODE19 (OR= 0.11, 95% CI= 0.06–0.21
P-value= 1.1 × 10−11). We also observed the association in
FinnGen (OR= 0.89, 95% CI= 0.82–0.97, P-value= 1.0 × 10−2),
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although the evidence was much less strong. The Columbus
study19 is a case–control study of thyroid cancer (1580 cases and
1628 controls) with much higher thyroid cancer prevalence than
the three population-based biobanks: UKBB30,31 (358 cases and
407,399 controls), FinnGen (501 cases and 135,137 controls), and
deCode19 (1003 cases and 278,991 controls). In Fig. 2, the
prevalence of thyroid cancer (left panel) and OR of thyroid cancer
(right panel) are plotted against the TSH PGS for the three
population-based cohorts (results for Columbus are provided in
Supplementary Fig. 10). Similar plots of hypothyroidism and
goiter are plotted for UKBB and FinnGen in Supplementary
Figs. 11 and 12.
Mendelian randomization for TSH, thyroid cancer, and goiter.
We investigated a possible causal effect of TSH on thyroid cancer
using two-sample Mendelian randomization. Ninety-four non-
HLA genetic variants for TSH identified by our meta-analysis of
HUNT, MGI and ThyroidOmics were used as instrumental
variables (F-statistic for all single nucleotide polymorphisms
(SNPs) > 23.72, rs1265091 and rs3104389 are HLA variants, and
the summary statistics for thyroid cancer were not available for
rs121908872, rs4571283, and 23:3612081). To avoid sample
overlap for the TSH and thyroid cancer GWASs, we used effects
on TSH estimated by meta-analyzing HUNT and ThyroidOmics
to construct the instrumental variable for TSH levels and we
meta-analyzed MGI, deCODE, and UKBB for thyroid cancer. We
found that a one SD increase in TSH (SD= 1.036 mU/L) was
associated with a 45% decreased risk of thyroid cancer (inverse-
variance weighted OR 0.55, 95% CI 0.40–0.74, MR-Egger inter-
cept P-value= 0.54). Sensitivity analyses using the penalized
weighted median method, the weighted median method and the
weighted mode method including all variants are presented in
Fig. 3a and Supplementary Data 14. Similar results were observed
between methods, with the exception of the weighted mode,
which was strongly attenuated. To reduce the possibility that the
results were influenced by occult thyroid dysfunction (typically
occurring in older age), we repeated the analysis using SNP-TSH
effect estimates obtained among those younger than 50 years of
age at the time of TSH measurement (Supplementary Data 15).
Similar results were observed, except for the weighted mode
which was again attenuated towards the null (OR 1.02, 95% CI
0.82–1.27, Supplementary Data 16). Furthermore, there was
strong evidence of heterogeneity, suggesting some instruments
were invalid. Nevertheless, when repeating the main analysis
using MR-PRESSO, which excluded nine variants due to the
detection of specific horizontal pleiotropic outlier variants54, the
causal association was similar (MR-PRESSO outlier corrected OR
0.65, 95% CIs 0.55–0.77) (Fig. 3a and Supplementary Data 14).
Finally, using only the protein-coding nonsynonymous variant p.
P118L in the TG gene (F-statistic= 114.89), we observed a pro-
tective effect of increased TSH on thyroid cancer (Wald ratio, OR
0.23, 95% CI 0.09–0.64). To investigate if TSH may also influence
the risk of benign thyroid growth disorders, we similarly per-
formed a two-sample Mendelian Randomization analysis
between TSH and goiter. The effects on TSH were estimated by a
meta-analysis of HUNT and ThyroidOmics (Supplementary
Data 1 and 2) and the GWAS results for goiter from the UKBB
were used27,28. A 1 SD increase in TSH (SD= 1.036 mU/L)
was associated with a 72% decreased risk of goiter (inverse-var-
iance weighted OR 0.28, 95% CI 0.20–0.41, MR-Egger intercept
P-value= 0.73) (Fig. 3b and Supplementary Data 17).
Discussion
Meta-analysis of the HUNT study, the MGI biobank and the
ThyroidOmics consortium for TSH on up to 119,715 individuals
identified 74 TSH loci, of which 28 are previously unreported. All
TSH loci reported by previous GWAS studies17,22,23 are repli-
cated in our meta-analysis. Several novel loci pointed to nearby
genes with a known or suspected link to thyroid function.
Additional independent signals were identified among several loci
based on GWAS results in the meta-analysis and LD information
in the HUNT study, including two rare variants rs546738875 and
rs145153320 at the B4GALNT3 locus and two rare missense
variants TSHR p.A553T (rs121908872) and TSHR p.R609Q
(rs139352934), which have been observed to be associated with
congenital hypothyroidism in previous family studies36,37. TSHR
p.R609Q (rs139352934) is the most strongly associated with TSH
in the TSH receptor gene TSHR with an effect size greater than
one standard deviation of TSH (1.036 mU/L). As these rare var-
iants were only imputed in HUNT, not in MGI or ThyroidOmics,
further follow-up to verify the associations is needed. As indivi-
dual GWAS was conducted on inverse-normal transformed TSH
levels before meta-analysis, it is challenging to convert the effect
sizes reported by our meta-analysis to actual scales of TSH levels.
Fine-mapping for potential causal variants among TSH loci
detected two independent missense variants in the TG gene TG:
p.G67S and p.P118L. The two variants have a similar frequency
(~2%), but p.P118L shows stronger evidence for an association
with goiter and with thyroid cancer. Functional experiments
demonstrated each of these defects in the TG gene, p.P118L and
p.G67S respectively, causes defective secretion of TG. Further
studies are needed to investigate how the protein-altering variants
impact TSH levels.
As expected, membranes and thyroid gland were identified as
the tissue in which genes from TSH-associated loci are most likely
to be highly expressed. Genes ZFP36L2, B4GALNT3, PPP1R3B,
FAM109A, GNG12, GADD45A, BMP2, VEGFC, LPP, and MAL2
were prioritized as functional candidates among the novel TSH-
associated loci based on functional similarity to other genes at all
TSH loci using DEPICT47.
A PheWAS of the TSH-associated variants in the UKBB
demonstrated that TSH-increasing alleles are associated with an
increased risk of cardiovascular disease, smaller body size,
reduced bone mineral density, decreased lung function and an
increased risk of hypothyroidism, but were favorably associated
with a decreased risk of goiter. Our results suggest that these
variants have pleiotropic effects, although they tend to affect TSH
through actions in the thyroid gland.
Phenome-wide association tests in the UKBB and FinnGen for
the TSH PGS showed that genetically predicted increased TSH is
associated with a high risk of hypothyroidism and a low risk of
goiter, thyrotoxicosis, hyperhidrosis, and thyroid cancer. Two-
sample Mendelian randomization analyses suggested that lower
TSH causes an increased risk of thyroid cancer and goiter. This is
an unexpected direction, given that TSH promotes the growth of
thyroid cancers8,14–16. Nonetheless, it has previously been
speculated that lower TSH levels may lead to less differentiation
of the thyroid epithelium, which could predispose to malignant
transformation17. Alternatively, our genetic instrument for TSH
may represent a thyroid gland phenotype that influences both
TSH (through the negative feedback of thyroid hormones on the
pituitary gland) and thyroid growth (increasing the risk of thyroid
cancer and goiter) (Supplementary Fig. 13). In that scenario, the
effect on thyroid cancer would not be downstream of TSH, and
altering TSH levels (e.g., by medication) would not be expected to
alter thyroid cancer risk. Tissue enrichment analyses of genes at
TSH-associated loci and the observation that TSH-lowering
alleles were generally associated with higher free thyroxine levels
(Supplementary Data 9) suggest that most TSH-associated var-
iants act primarily on the thyroid gland, where effects on both
thyroid function and growth have previously been described for
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TSHR mutations55. Nonetheless, the Mendelian randomization
findings were robust to most of the sensitivity analyses performed
to detect and correct for pleiotropy. Restricting the genetic
instrument to TSH-lowering variants associated with lower free
thyroxine levels could have helped resolve the causal question, but
those variants were too few to yield meaningful estimates with
current data.
Although our results suggest that interventions elevating TSH
levels could potentially reduce thyroid cancer risk, this suggestion
lacks evidence from intervention studies. Further, any interven-
tion that increases TSH levels by inhibiting thyroid hormone
production would expectedly lead to symptoms and signs of
hypothyroidism. Note that phenotype heterogeneity between the
thyroid cancer data sets could have an impact on our results,
although associations between higher TSH PGS and reduced
thyroid cancer risk were observed in all four study populations.
Different approaches were used to curate phenotypes for thyroid
cancer, with cases being identified based on ICD codes mapped to
PheCodes in the UKBB28,56, ICD codes combined with popula-
tion registries in FinnGen and the Icelandic Cancer Registry
(ICR) in the Icelandic data set19, while the papillary or follicular
thyroid carcinoma (PTC) cases were histologically confirmed in
the Columbia, USA, data set19.
Our findings suggest that the majority of identified TSH-
associated variants act through pathways regulating both thyroid
function and thyroid growth. Additional experiments are needed
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to fully disentangle the role of TSH-associated variants in thyroid
cancer and goiter, such as examining their associations with other
thyroid traits (e.g., free thyroxine levels) through large GWASs.
Methods
HUNT. The HUNT study is a longitudinal, repeatedly surveyed, population-based
health study conducted in the county of Nord-Trøndelag, Norway, since 198416.
Approximately 120,000 individuals have participated through 3 phases of HUNT
surveys with phenotype measurements: HUNT1 (1984–86), HUNT2 (1995–97),
and HUNT3 (2006–08). About 70,000 HUNT participants with DNA collected have
been genotyped using Illumina HumanCoreExome v1.0 and 1.1, and imputed using
Minimac3 with a merged reference panel of Haplotype Reference Consortium
(HRC)57 and whole genome sequencing data for 2201 HUNT samples. Variants
with imputation r2 < 0.3 were excluded from further analysis. The population is
considered to be iodine sufficient58. TSH was measured using DELFIA hTSH Ultra
from Wallac Oy (Turku, Finland) in HUNT2 and a chemiluminescent microparticle
immunoassay on an Architect ci8200 from Abbott (Abbott Ireland, Longford,
Ireland; and Abbott Laboratories, Abbott Park, IL) in HUNT3; the two measure-
ment methods yielded similar results59. TSH measurements were available for
55,342 individuals who were genotyped (54.4% are females), after excluding those
with thyroid disorders based on self-report, blood tests indicating clearly overt
hypothyroidism (TSH ≥ 10mU/L combined with free T4 < 9 pmol/L; undiagnosed
overt autoimmune hypothyroidism was relatively common at the time of
HUNT259) and cancer registry data (7.34%). If TSH was measured in both HUNT2
and HUNT3, the earlier HUNT2 measure was used. The mean age at TSH mea-
surement is 51.79 years. The mean TSH in HUNT is 1.659mU/L and SD is 1.036
mU/L. We performed genome-wide association analysis for inverse-normalized
TSH on 20.7 million markers based on the linear mixed models using SAIGE28 to
account for sample relatedness. We used TSH batch (indicating whether TSH was
measured in HUNT2 or HUNT3), genotyping batch, the first fifteen genetic prin-
cipal components (PCs) (which account for 85% of the genetic variance among
study samples), age at the measurement of TSH and sex as covariates. In a sensi-
tivity analysis, we excluded HUNT participants with TSH outside the reference
range (0.5–4.5mU/L), and results were similar to the main analysis (Supplementary
Data 15). Participation in HUNT is based on informed consent and the study has
been approved by the Norwegian Data Protection Authority and the Regional
Committee for Medical and Health Research Ethics in Central Norway.
Michigan Genomics Initiative. The MGI is a repository of electronic health and
genetic data collected from patients at Michigan Medicine during pre-surgical
encounters, who have consented to linking of genetic and clinical data for research
purposes26. Participants were genotyped using Illumina Infinium CoreExome-24
bead arrays and genotype data were imputed to the HRC using the Michigan
Imputation Server. Unrelated individuals with European ancestry were used for the
GWAS on TSH levels. MGI participants (16,003) have at least one TSH mea-
surement. Then, 5918 of these individuals with any thyroid disorders were
excluded based on the ICD9 and ICD10 codes mapped to PheCodes52 193 (thyroid
cancer), 244 (hypothyroidism), 245 (thyroiditis), and 246 (other disorders of
thyroid), leaving 10,085 samples in the association analysis (53.4% are females). If
more than one TSH measurement for an individual was available in the electronic
health records, we used the average of the TSH levels for the individual in the
analysis. The mean and SD for TSH in MGI are 1.914 and 1.175 mU/L, respec-
tively. The mean age at TSH measurement is 55.90 years. We performed single-
variant association testing of the inverse-normalized TSH levels on 17 million
variants using a linear regression model as implemented in EPACTS with first four
PCs, age, and sex as covariates. Later, we also performed single-variant association
testing of thyroid cancer on the TSH-associated index variants using a logistic
mixed model as implemented in SAIGE28 with first 4 PCs, age and sex as
covariates.
ThyroidOmics. The data set consists of a large meta-analysis for TSH performed
by the ThyroidOmics consortium [http://www.thyroidomics.com] for up to
54,288 subjects of European ancestry23. Briefly, genotype data in 22 independent
cohorts were imputed to 1000 Genomes, phase 1 version 360. Eight million genetic
markers were examined for association with inverse-normalized normal-range
TSH levels in the meta-analysis including variants with MAF ≥ 0.5% and impu-
tation score ≥ 0.4.
UK Biobank. The UKBB is a population-based cohort across the United King-
dom27. Non-sex-specific binary phenotypes (1283) have been constructed based on
ICD9 and ICD10 codes mapped to PheCodes28,56.
FinnGen. FinnGen is a public–private partnership project combining genotype
data from Finnish biobanks and digital health record data from Finnish health
registries (https://www.finngen.fi/en). Release 3 analysis contains 135,638 samples
after quality control with population outliers excluded via PC analysis based on
genetic data. Endpoints (1801) have been constructed from population registries
and ICD10, and harmonizing definitions over ICD8 and ICD9.
deCODE. The data set contains 279,994 Icelandic participants of European
ancestry at deCODE (1003 non-medullary thyroid cancers and 278,991 controls)19.
The non-medullary thyroid cancer cases were identified from the ICR (http://www.
krabbameinsskra.is/indexen.jsp?icd=C73). The mean age at diagnosis is 53 years
for cases and the mean age of controls is 57 years19.
Columbus, USA. The Columbus, USA, study contains 1580 patients with self-
reported European ancestry histologically confirmed papillary or follicular thyroid
carcinoma and 1628 controls19. The mean age at diagnosis is 43 years for cases and
the mean age of controls is 45 years.
Meta-analysis. We performed fixed-effect meta-analysis based on inverse-variance
weighting for HUNT, MGI, and ThyroidOmics in METAL61. Cochran’s Q-test62
for heterogeneity has been conducted using METAL61. We performed genomic
control correction prior to and after the meta-analysis. We identified LD-
independent genomic loci using LD-clumping based on association P-values from
the meta-analysis using PLINK (–clump-r2= 0.2 –clump-kb= 500 –clump-p1=
5e-08 –clump-p2= 5e-02). Overlapping loci were merged together. 1000 Genomes
EUR60 population was used as the reference panel for estimating LD.
Stepwise conditional analysis. We identified additional independent association
signals at each locus using an approximate stepwise conditioning approach in
GCTA-COJO29 (--cojo-slct) and reported top variants with conditional P-values ≤
5 × 10−8.
Gene-based association tests. We performed gene-based SKAT-O tests using
SAIGE-GENE38,39 for 10,071 genes with at least two copies of missense and stop-
gain alleles with MAF ≤ 0.5% and imputation quality score ≥ 0.8 in HUNT. We
used the same covariates as the single-variant association tests: the first 15 PCs, age,
sex, genotyping batch, and TSH measurement batch.
Variant annotation and fine-mapping. We annotated genetic variants using
ANNOVAR63. We performed fine-mapping at all TSH loci using SuSiE40, which
estimated the number of causal variants and the 95% credible sets for each locus.
Variance of TSH explained by loci. We estimated the variance of TSH explained
by TSH-associated loci as sum of effect size2 × 2 ×MAF × (1−MAF) for all
independent top hits, where effect size is in the unit of SD of TSH.
Gene-enrichment tests. We performed gene set and tissue enrichment analysis
using DEPICT47. We included variants with association P-values < 1 × 10−5 based
on the meta-analysis of HUNT, MGI, and ThyroidOmics in DEPICT. We used LD
information from the European subsets of 1000 Genomes to construct loci within
DEPICT.
Phenome-wide association test. For all 95 identified TSH index variants (in
known or novel TSH loci; 4 out of 99 variants were excluded: rs1265091 and
rs3104389 are HLA variants, and rs121908872 and 23:3612081 were not in UKBB),
we carried out look-ups for their association with 1283 human diseases/condi-
tioned constructed based on PheCodes mapped to ICD codes27,28,48 and 274
quantitative traits (inverse ranked normalized, GWAS results from the Neale Lab)
in the UKBB. We reported associations with P-value < 5 × 10−8.
Polygenic score. We computed PGS for TSH based on non-HLA significant index
variants weighted by the effect size estimates from the meta-analysis of HUNT,
MGI, and ThyroidOmics23. We excluded four index variants from the UKBB
analysis because two were not available in UKBB (rs121908872 and 23:3612081)
and two were located in the HLA region (rs1265091 and rs3104389). We con-
structed TSH PGS for 408,961 participants with White British ancestry in UKBB
and tested for associations with 1283 binary phenotypes27,28,48 using a logistic
mixed model as implemented in SAIGE28 with birth year, sex, and first four genetic
PCs as covariates. We also constructed TSH PGS for 135,638 participants in
FinnGen release 3 on the 87 non-HLA index variants (the HLA variants rs1265091
and rs3104389 were excluded from the analysis, 10 variants were not available in
FinnGen r3: rs12027702, rs12138950, rs145153320, rs141751376, rs121908872,
rs139352934, rs191633940, rs4571283, rs118039499, and 23:3612081) and tested
for associations with 1801 binary phenotypes using a logistic mixed model as
implemented in SAIGE28 with age, sex, first ten genetic PCs and genotyping batch
as covariates. In addition, we constructed TSH PGS for two previously reported
thyroid cancer study populations and tested for associations with the risk of
thyroid cancer: the Columbus, USA, study containing 1580 patients with self-
reported European ancestry histologically confirmed papillary or follicular thyroid
carcinoma and 1628 controls19, and the Icelandic cohort with 1003 cases and
278,991 controls from deCODE19. In each data set, subjects were divided into
quintiles according to their TSH PGS. OR (with 95% CI) of thyroid cancer was
estimated for each quintile using the lowest quintile as the reference. The
Nagelkerke’s r2 of TSH PGS for phenotypes in the UKBB was estimated as the
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difference of r2 in the full models with PRS and non-genetic covariates birth year,
sex, and first four genetic PCs and r2 in the reduced models with non-genetic
covariates only without PRS using the R library rcompanion.
Mendelian randomization. We performed two-sample Mendelian randomization
using summary data for 94 significant independent variants for TSH from the
meta-analysis of HUNT and the ThyroidOmics consortium23. We excluded five
SNPs from the analysis because they were not available in the thyroid cancer meta-
analysis (rs121908872, rs4571283, and 23:3612081) or were located in the HLA
region (rs1265091 and rs3104389). For the analysis, we calculated SNP-TSH effect
estimates from the meta-analysis of HUNT and ThyroidOmics in up to
109,630 samples, excluding individuals with thyroid disorders. We calculated SNP-
thyroid cancer effect estimates from the meta-analysis of UKBB24, MGI, deCODE,
and four other case–control data sets with European ancestry as reported in
Gudmundsson et al.19 (total number of cases/controls= 4146/731,903). We cal-
culated SNP-goiter estimates from UKBB (1143 cases and 391,429 controls). We
calculated the F-statistic to assess the strength of the instruments, where values >10
are indicative of adequate strength. We applied inverse-variance weighted, pena-
lized weighted median, weighted median, weighted mode and pleiotropy residual
sum and outlier methods using MR-Base64 and MR-PRESSO54. The seven variants
detected as outliers in the main analysis and excluded from the MR-PRESSO
analysis were rs11156905, rs116909374, rs2993047, rs2928167, rs1479567,
rs73234178, and rs925488.
Materials. Fetal bovine serum, ampicillin, and dithiothreitol (DTT) were from
Sigma. QuikChange lightning site-directed mutagenesis kit was from Agilent.
Plasmid purification kits were from Zymo Research. Protease inhibitor cocktail was
from Roche. Penicillin/streptomycin, phosphate-buffered saline (PBS), and Dul-
becco’s modified Eagle’s medium (DMEM) were from Gibco. Lipofectamine 2000
and subcloning efficiency DH5α-competent cells were from Invitrogen; LB broth
base LB agar was from BD Difco.
Mutagenesis of TG gene by PCR. Utilizing the QuikChange Primer Design
Program, we designed mutagenic primers (from Integrated DNA Technologies):
RP.G67S, 5′-ccagcaagattgactatcattttggcattggactgtctgg-3′
FP.G67S, 5′-ccagacagtccaatgccaaaatgatagtcaatcttgctgg-3′
RP.P118L, 5′-ctgaatcctggcactgaagaaggtagagagcatcg-3′
FP.P118L, 5′-cgatgctctctaccttcttcagtgccaggattcag-3′
We incorporated PCR primers with the indicated point mutations using the
QuickChange PCR mutagenesis kit as per the manufacturer’s instructions (Agilent
Technologies). We used the mTG cDNA sequence (NCBI database Reference
Sequence: NM_009375.2) in the pcDNA3.1 expression vector as a template for
primer design. We performed mutagenesis by PCR in a 2710 Thermal Cycler
(Applied Biosystems) and confirmed mutations by DNA sequencing.
Transient transfection and cell culture. We cultured 293T cells in DMEM with
10% fetal bovine serum at 37 °C in a humidified 5% CO2 incubator. We seeded
293T cells at 50,000 cells/well in 24-well plates 24 h prior to transfection and
transiently transfected 500 ng of plasmid DNA per well using Lipofectamine 2000
transfection reagent according to the manufacturer’s instructions. At 24 h post
transfection, we washed the cells with PBS and re-fed with fresh serum-free media
and incubated overnight. We collected bathing media and lysed the cells in RIPA
buffer containing protease inhibitor cocktail.
Western blotting. We subjected samples to SDS-PAGE under reducing condi-
tions, electrotransfer to nitrocellulose, and incubated in blocking buffer. We diluted
primary antibody, rabbit polyclonal anti-TG 1:5000 in 5% bovine serum albumin/
TBS-T and incubated for 1 h at room temperature. We incubated anti-rabbit
horseradish peroxidase-conjugated secondary antibody (1:5000 dilution in blocking
buffer) for 30 min at room temperature. We visualized bands using the Wester-
nBright Sirius kit (Advansta) and captured digital images (~5 s) in a Fotodyne
workstation. We assessed differences in extracellular:intracellular mTg ratio (M/C,
a value that is independent of transfection efficiency) using two-sample unpaired t-
tests. P-value < 0.025 was declared significant with multiple testing taken into
account, as two independent tests were conducted, one compared Tg-P118L var-
iant to WT and the other one compared Tg-G67S to wild type. Full scans of
western blottings are provided in Supplementary Fig. 14.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Data generated or analyzed during this study are available from the corresponding
authors upon reasonable request, but access to individual-level information from the
included studies may require approval from the individual studies and from the relevant
research ethics committee due to privacy issues. Meta-analysis TSH summary statistics
are available at http://csg.sph.umich.edu/willer/public/TSH2020/.
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